What are the ECG criteria for diagnosing supraventricular tachycardia (SVT) with aberrancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ECG Criteria for SVT with Aberrancy

When evaluating a wide-complex tachycardia (QRS >120 ms), SVT with aberrancy is suggested when the QRS morphology in tachycardia is identical to the QRS seen during sinus rhythm, indicating pre-existing bundle branch block or rate-related aberrant conduction. 1

Key Diagnostic Features Supporting SVT with Aberrancy

Primary Criteria

QRS morphology comparison is the most reliable criterion:

  • QRS complexes in tachycardia that match sinus rhythm strongly suggest SVT with aberrancy 1
  • This indicates either pre-existing bundle branch block or rate-dependent aberrant conduction that normalizes when heart rate slows

Specific ECG Patterns

In lead V1 with right bundle branch block (RBBB) morphology:

  • rsR' pattern (triphasic) suggests SVT with aberrancy 1
  • This classic RBBB pattern is more consistent with supraventricular origin
  • Monophasic R wave is NOT valuable for diagnosing VT 2

Absence of VT criteria:

  • No AV dissociation (atrial rate slower than ventricular rate)
  • No fusion or capture beats
  • R-S interval <100 ms in all precordial leads
  • QRS width <140 ms (though this alone is not diagnostic) 2
  • No concordance (all QRS complexes in precordial leads not uniformly positive or negative)
  • R-wave peak time in lead II <50 ms 1

Additional Supporting Features

Rate considerations:

  • Tachycardias >190 bpm often lack unequivocal criteria for differentiation 2
  • Aberrancy is rate-dependent and should normalize when heart rate decreases

Clinical context matters:

  • Younger patients without structural heart disease favor SVT
  • Absence of prior myocardial infarction supports SVT diagnosis 3

Critical Pitfalls

Do not rely on single-lead assessment: The MCL1 lead cannot substitute for V1 and shows different QRS morphology in 40% of VT cases 2. Multiple leads are essential for accurate diagnosis.

Approximately 10% of wide-complex tachycardias defy differentiation using standard ECG criteria alone 2, 4. In these cases, invasive electrophysiology study may be necessary 5.

Conventional criteria have reduced sensitivity for idiopathic VT: Standard criteria correctly identify only 82% of idiopathic VT (versus 95% of post-MI VT), particularly when VT originates from septal or Purkinje sites 6. This means some VTs may appear to meet SVT criteria.

Algorithmic Approach

  1. Compare tachycardia QRS to sinus rhythm QRS - if identical, strongly favors SVT with aberrancy
  2. Assess for AV dissociation - if absent, more consistent with SVT
  3. Examine V1 morphology - rsR' pattern supports SVT with RBBB aberrancy
  4. Check precordial leads - absence of concordance supports SVT
  5. Measure R-S intervals - all <100 ms supports SVT
  6. When uncertain, treat as VT - safer approach given that VT accounts for >80% of wide-complex tachycardias 3

Remember: Hemodynamically unstable patients require immediate cardioversion regardless of rhythm diagnosis 1, 7. Diagnostic precision should never delay life-saving treatment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.